Guggenheim Reiterates Buy Rating on Endava

Summary

Guggenheim reiterated its ‘buy’ rating on Endava (NYSE: DAVA) with a price target of $25.00, suggesting a potential upside of 46.03%. The stock is currently trading at $17.12, having risen by 3.3%. Other analysts are mixed, with six holding ratings and three buy ratings. Endava’s market cap is $1.01 billion with a P/E ratio of 155.34, and institutional investors own 62.23% of the shares. The company provides technology services in various sectors, including healthcare and retail. Market Beat+ 2

Impact Analysis

This is a company-level event, as it specifically pertains to Endava and its stock rating by Guggenheim. The reaffirmation of the ‘buy’ rating and the set price target ($25.00) signals Guggenheim’s confidence in Endava’s future performance, potentially influencing investors to consider buying or holding the stock. Other analyst ratings vary, with an average target price of $23.08, indicating a general positive sentiment but with some caution. The stock’s recent price increase of 3.3% reflects immediate market optimism. First-order effects include potential increased demand for Endava’s shares due to the positive rating and anticipated price appreciation. Second-order effects could involve increased visibility and interest from other institutional investors, given the 62.23% institutional ownership, possibly leading to further price movements. Investment opportunities primarily lie in the direct purchase of Endava’s stock, while risks include the high P/E ratio, reflecting high expectations and potential volatility. Market Beat+ 3